UMC's 28nm Ramp to Slip This Year
Alan Patterson, EETimes
1/24/2017 04:40 PM EST
TAIPEI — United Microelectronics Corp. (UMC), Taiwan’s second largest foundry, said the ramp of its most advanced node, 28nm, will probably slip during the early portion of 2017 under strong competition.
UMC, which competes with larger rival Taiwan Semiconductor Manufacturing Co. (TSMC) and smaller foundries in China in 28nm said that its first wave of customers at that geometry have migrated to more advanced nodes at the same time as an expected second wave of customers have been slower to adopt chips made with the process technology.
While UMC reached its 2016 target for 28nm to account for 17 percent of the company’s overall sales, that percentage is likely to slide downward during the first quarter. The company last year said that 28nm would reach as much as 20 percent of overall sales during 2016.
|
|
E-mail This Article |
|
Printer-Friendly Page |
|
||||||
Related News
- eMemory and UMC Qualify NeoFuse IP on the Foundry's 28nm High Voltage Process
- UMC Meets Expectations on 28nm Ramp as Demand Slumps
- UMC Cuts Expectations for 28nm Ramp on Weaker Demand
- UMC Adopts Synopsys IC Validator for Pattern Matching-Based Lithography Hot-Spot Verification at 28 nm
- UMC Qualifies Synopsys' IC Validator for 28-nm Physical Verification
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design






